



PROMISE PROTEOMICS SAS

7, parvis Louis Néel • BHT 52 A • CS 20050 - 38040 Grenoble Cedex 9 • FRANCE

Phone +33 4 38 02 36 50

contact@promise-proteomics.com

RCS Grenoble B 433 546 504

The logo for mAbXmise features the text "mAbXmise" in a lowercase, sans-serif font. Above the "Ab" part of the text is a stylized bar chart with four vertical bars of varying heights and colors: blue, purple, green, and red. The "X" in "mAbXmise" is a red, stylized character that overlaps the "Ab" and "mise" parts of the text.

mAbXmise

SALES CATALOG

DEVELOPED BY
promise
ADVANCED PROTEOMICS

PROM-0012.V01-04.23



QUANTIFICATION OF MONOCLONAL ANTIBODIES

The mAbXmise quantification kit is intended to monitor the concentration of therapeutic monoclonal antibodies (mAbs) in samples from patients treated with these mAbs. The kit is a quantitative assay.

INCLUDED IN EACH KIT

- 96-well plate coated with stable labelled mAbs (internal standards)
- 6 calibrators (CAL)
- 2 Quality Control samples (QC)
- Relevant buffers and solutions
- Specific consumables
- Protease

KITS TO MEASURE BLOOD CONCENTRATION OF THERAPEUTIC MONOCLONAL ANTIBODIES

MONOCLONAL ANTIBODY	PRODUCT REFERENCE						
	OTDM1	ITDM1	ITDM2	GTDM	HTDM	PNHTDM	IADA1
• Bevacizumab	✓						
• Rituximab	✓						
• Cetuximab	✓						
• Trastuzumab	✓						
• Nivolumab	✓						
• Pembrolizumab	✓						
• Ipilimumab	✓						
• Infliximab		✓	✓				
• Adalimumab		✓	✓				
• Obinutuzumab			✓				
• Secukinumab			✓				
• Tocilizumab			✓				
• Ustekinumab			✓				
• Vedolizumab			✓				
• Abatacept				✓			
• Belatacept				✓			
• Emicizumab					✓		
• Eculizumab						✓	
• Ravulizumab						✓	
• ANTI-Infliximab							✓
• ANTI-Adalimumab							✓

The mAbXmise quantification kits are intended to monitor the concentration of therapeutic monoclonal antibodies (mAbs), Infliximab, Adalimumab, Obinutuzumab, Secukinumab, Tocilizumab, Ustekinumab, Vedolizumab, Bevacizumab, Cetuximab, Rituximab, Trastuzumab, Nivolumab, Pembrolizumab, Ipilimumab, Belatacept, Abatacept, Emicizumab, Eculizumab, Ravulizumab, ANTI-Infliximab and ANTI-Adalimumab, in samples from patients treated with these mAbs. The kit is a quantitative assay. The test can be performed on plasma (EDTA, heparin or citrate collection tubes) and serum. Assay results are intended to be used by healthcare professionals. Before use, it is important to carefully read the instructions provided with the product. This document is a sales catalog.